Redeye: Nanologica Q2 2025 - Low near-term visibility but encouraging long-term case
RefinitivMeno di 1 minuto di lettura
Redeye updates its view on Nanologica following the Q2 report. While near-term visibility remains limited, the company continues to build a solid foundation for the long-term case. The potential announcement of new production customers in H2 could pave the way for strong sales growth. Based on our updated estimates, the share is trading at 1.1x 2026e EV/S.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Accedi o crea un account gratuito per leggere queste notizie